- £81.91bn
- £95.80bn
- £32.67bn
REG - GSK PLC - GLISTEN Trial of Linerixibat Meets Endpoint
AnnouncementREG - GSK PLC - GSK announces overall survival results for Blenrep
AnnouncementREG - GSK PLC - Block listing Interim Review
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - GSK publishes provisional 2025 dividend dates
AnnouncementREG - Allianz Global Invs - Top 10 Holdings
AnnouncementREG - GSK PLC - Total Voting Rights
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - 3rd Quarter Results
AnnouncementREG - GSK PLC - New positive Arexvy data in younger adults at risk
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - FDA accepts new drug application for gepotidacin
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Positive results of ANCHOR trials of depemokimab
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Director/PDMR Shareholding
AnnouncementREG - GSK PLC - Zantac (ranitidine) litigation settlements
AnnouncementREG - GSK PLC - Positive efficacy data of Arexvy over 3 seasons
Announcement